A 24-week, open-label, multicenter study of patients with schizophrenia who switch to aripiprazole once-monthly from oral antipsychotics or from other long-acting injections, examining changes in functioning, quality of life, symptoms, and sexual function.

Sponsor: Korea Otsuka Pharmaceutical

An open-label extension study evaluating the long-term safety of once-daily iclepertin in patients with schizophrenia who completed a previous phase 3 trial.

Sponsor: Boehringer Ingelheim

A 26-week, randomized, double-blind, placebo-controlled trial of iclepertin, a glycine transporter 1 inhibitor, on cognition and functional capacity in patients with schizophrenia.

Sponsor: Boehringer Ingelheim

A trial evaluating the efficacy and safety of WID-RGC20 at 3 mg/day and 6 mg/day in patients with schizophrenia experiencing an acute psychotic episode.

Sponsor: Whanin Pharmaceutical

A trial evaluating the efficacy and safety of MK-8189 in patients with an acute episode of schizophrenia.

Sponsor: MSD

A 6-week, randomized, double-blind, active-controlled trial testing the noninferiority of lurasidone to quetiapine XR in Korean patients with schizophrenia experiencing acute psychotic symptoms.

Sponsor: Bukwang Pharmaceutical

Results: Kim et al., Psychiatry Investig, 2024.

An open-label study evaluating the efficacy and safety of switching from oral atypical antipsychotics to aripiprazole once-monthly in patients with schizophrenia.

Sponsor: Korea Otsuka Pharmaceutical